Meeting
2019 ASCO Annual Meeting
The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT).
Authors
Nitin Ohri
Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
Nitin Ohri , Haiying Cheng , Shruti Jolly , Shirish M. Gadgeel , Benjamin Thomas Cooper , Elaine Shum , Balazs Halmos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03523702
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS8571)
DOI
10.1200/JCO.2019.37.15_suppl.TPS8571
Abstract #
TPS8571
Poster Bd #
326a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.
First Author: Nitin Ohri
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2021 ASCO Quality Care Symposium
Real-world trends in EU4 and the UK in frontline (1L) maintenance (MT) for nonsquamous (NSQ) advanced non-small cell lung cancer (aNSCLC) without actionable mutations after introduction of immune checkpoint inhibitors.
First Author: Cosmina Hogea